For a patient discharged home for outpatient intravenous ertapenem infusion to treat ESBL‑producing Klebsiella recurrent urinary tract infections, should nitrofurantoin be discontinued at discharge?

Discontinue Nitrofurantoin at Discharge

Yes, discontinue nitrofurantoin from the home medication list when discharging this patient on outpatient ertapenem for ESBL-producing Klebsiella recurrent UTIs. The patient is receiving definitive IV carbapenem therapy that provides complete coverage, and continuing nitrofurantoin offers no additional therapeutic benefit while potentially causing unnecessary adverse effects and medication confusion.

Rationale for Discontinuation

Ertapenem Provides Complete Coverage

Ertapenem is a broad-spectrum carbapenem with excellent activity against ESBL-producing organisms, including Klebsiella pneumoniae 1. The patient is receiving definitive treatment with once-daily IV ertapenem, which achieves high urinary concentrations and effectively treats the documented pathogen 2. Adding oral nitrofurantoin provides no incremental antimicrobial benefit when the patient is already on appropriate IV therapy.

Nitrofurantoin Has Limited Activity Against Klebsiella

While nitrofurantoin demonstrates excellent activity against E. coli (including ESBL-producing strains), its spectrum is notably narrow and primarily covers E. coli and S. saprophyticus 3. Recent data show concerning limitations:

• Klebsiella pneumoniae demonstrates significantly reduced susceptibility to nitrofurantoin compared to E. coli 4, 5
• In pediatric ESBL-positive isolates, K. pneumoniae had MIC50/MIC90 of 64/128 μg/mL for nitrofurantoin—at or above the resistance breakpoint 4
• Clinical outcomes with ertapenem for Klebsiella UTIs show lower microbiological cure rates compared to E. coli (OR 0.21, p=0.029) 2, suggesting Klebsiella requires more aggressive therapy

Risk of Polypharmacy and Medication Errors

Continuing nitrofurantoin alongside ertapenem creates unnecessary polypharmacy without clinical benefit. This increases the risk of:

• Medication confusion during the OPAT course
• Duplicate therapy concerns if the patient doesn't understand one antibiotic is IV and one is oral
• Adverse effects from nitrofurantoin (GI upset, pulmonary toxicity with prolonged use) without therapeutic gain
• Non-adherence to the critical ertapenem regimen if the patient becomes confused about which medication is essential

Clinical Context: Recurrent UTI Management

After Ertapenem Course Completion

The question of nitrofurantoin becomes relevant after the ertapenem course is completed, not during it:

• For secondary prophylaxis: If the patient has documented recurrent UTIs and the organism was E. coli (not Klebsiella), nitrofurantoin could be considered for long-term prophylaxis after completing acute treatment 3, 6
• For future acute episodes: Nitrofurantoin remains first-line for uncomplicated cystitis caused by susceptible E. coli 3, but this patient has ESBL Klebsiella, which limits its utility

Important Caveats

Do not use nitrofurantoin for prophylaxis if:

• The recurrent pathogen is Klebsiella (as in this case)—nitrofurantoin has inadequate activity 4, 5
• The patient has CKD with CrCl <30 mL/min—nitrofurantoin is contraindicated 7
• The patient has complicated UTI or upper tract involvement—nitrofurantoin achieves minimal tissue/serum levels 6

Practical Discharge Plan

At discharge:

1. Remove nitrofurantoin from the active medication list
2. Ensure OPAT coordination for daily ertapenem administration (typically 1g IV daily) 8, 2
3. Document the pathogen (ESBL Klebsiella) and its susceptibilities in discharge paperwork
4. Counsel the patient that ertapenem is the only antibiotic needed during the treatment course
5. Plan follow-up urine culture 7-14 days after completing ertapenem to document microbiological cure

After ertapenem completion:

• If recurrent UTIs continue and future cultures grow E. coli (not Klebsiella), consider nitrofurantoin prophylaxis at that time
• If Klebsiella recurrence persists, alternative prophylactic strategies (not nitrofurantoin) should be discussed with urology/infectious disease

The evidence strongly supports discontinuing nitrofurantoin during active ertapenem therapy for ESBL Klebsiella, as it provides no benefit and introduces unnecessary risks 3, 9, 4, 2.